On April 19th, ASPEN became aware of a supply disruption of the valve set for the Baxter ExactaMix Automated Compounding Device. Please see the customer letter provided by Baxter here. For further details and questions, contact the Baxter Medical Affairs and Clinical Center of Excellence (CCoE) teams at [email protected].
ASPEN understands the unique nature of this supply disruption. We recognize the challenges and inherent patient safety concerns a device brings, compared to other parenteral nutrition product and component shortages. We encourage those impacted to develop an internal team to initiate conservation and mitigation plans.
ASPEN has collaborated with the American Society of Health System Pharmacists (ASHP), the Institute of Safe Medication Practices (ISMP), and the National Home Infusion Association (NHIA) to develop considerations for institutions and clinicians reliant on this device. The considerations are available here.
Posted April 29, 2022